Background. Chronic renal failure increases the risk of atherosclerosis. The clearance of low-density lipoprotein (LDL), a major risk factor for atherosclerosis, has been reported as being disturbed in dialysis patients. We studied LDL metabolism in non-dialyzed patients with chronic kidney disease (CKD). Methods. LDL clearance was studied with a radiotracer method in 57 CKD patients and 10 healthy controls. Results. In the CKD patients, the fractional catabolic rate of LDL apo B (LDL FCR), an indicator of LDL clearance from plasma, ranged from 0.13 to 0.56 pools/day with a mean value of 0.34 pools/day being comparable to that of the control subjects. In the renal patients, LDL FCR correlated significantly with estimated glomerular filtration rate (eGFR) (r = 0.340, P = 0.010) and this association remained significant after the adjustment with age, body mass index, gender, presence of diabetes and LDL cholesterol concentration (P = 0.004). In CKD patients with eGFR <15 mL/min/1.73 m 2 the mean LDL FCR was significantly reduced when compared to that of CKD patients with eGFR >30 mL/min/1.73 m 2 (P = 0.005). LDL apo B production rate was not associated with renal function or different between renal patients and control subjects.
Introduction
Patients with chronic renal failure are at a substantially elevated risk of developing atherosclerosis. Approximately 40% of these patients have cardiovascular disease even before they reach end-stage renal failure requiring dialysis therapy [1] . The risk of cardiac mortality has been shown to be elevated more than 100-fold among dialysis patients aged 45 years or younger compared to the general population [2] . Even mild renal impairment has been associated with an increased risk for death, cardiovascular events and hospitalization in the general population [3] , suggesting that cardiovascular disease begins to develop early in the course of chronic renal failure.
Chronic renal failure is characterized by multiple abnormalities in both the composition and the metabolism of plasma lipoproteins, and these changes are already evident in mild renal failure [4] [5] [6] [7] [8] [9] [10] . The levels of lowdensity lipoprotein (LDL) cholesterol remain normal or are only slightly elevated in uraemic dyslipidaemia [4, 7] . Previous research of LDL metabolism has focused mainly on dialyzed patients, and has found decreased LDL catabolism in patients on peritoneal dialysis [10] . Since the risk for cardiovascular disease (CVD) is enhanced even in mild and moderate renal impairment, the present study was designed to specifically investigate the metabolism of atherogenic LDL particles in patients with chronic renal failure with mild, moderate and severe renal impairment.
Subjects and methods

Study and control subjects
Patients of the outpatient clinic of Internal Medicine of Oulu University Hospital aged 18-70 years and with reduced glomerular filtration rate (GFR, measured with 99 mTc-DTPA, normal level over 75 mL/min/1.73 m 2 ) [11] together with either elevated serum creatinine (>115 µmol/L) or elevated serum urea (>8 µmol/L) values were identified. Subjects with the nephrotic syndrome (defined as proteinuria of 3 g/day or more in conjunction with serum albumin levels of <35 g/L and with oedema), familial hypercholesterolaemia (FH), liver disease, untreated thyroid disease or alcohol abuse were excluded. Eligible patients (N = 149) were sent a letter inviting them to participate, and 109 of them expressed initial interest. All patients gave informed consent for the investigations, which were approved by the Ethical Committee of the University of Oulu. The control group consisted of 10 healthy volunteers.
Measurements of renal function, lipids and lipoproteins
The serum urea and creatinine concentrations were determined with standard methods in the routine laboratory of Oulu University Hospital. Estimated GFR was calculated using the formula eGFR (mL/min/1.73 m 2 ) = 186 × (serum creatinine in mg/dL) −1.154 × (Age) −0.203 × (0.742 if female) [12] . Lipoprotein fractions were isolated by sequential ultracentrifugations from fasting venous blood samples as previously described [13] . HDL cholesterol was measured after precipitation with heparinmanganese [14] . LDL cholesterol was calculated by subtracting the HDL and the IDL cholesterol from the total cholesterol content of the VLDL infranatant. Cholesterol and triglyceride concentrations were determined using enzymatic colorimetric methods (kits by Boehringer Diagnostica, Mannheim GmbH, FRG). The protein contents of lipoproteins were measured by the method of Lowry et al. [15] . The plasma LDL apolipoprotein B (LDL apo B) level was determined after isopropanol precipitation [16] . For lipid analyses, blood samples were obtained three times 1 week apart, and the means of the three measurements were used.
LDL turnover studies
LDL turnover studies were carried out as previously described [7, 17] . Briefly, LDL was isolated from plasma with sequential ultracentrifugations and labelled with 125 I. This preparation was injected within 4 days of isolation and 2 days of iodination. Blood samples were obtained at 0, 15, 30 min and 1, 2 and 3 h after injection and three times a week for 14 days thereafter. Total plasma radioactivity was determined from each sample. The clearance rate of LDL apo B (i.e. the LDL FCR, defined as the intravascular pool of LDL cleared per time unit) was calculated from the plasma decay curves as described earlier [7, 17] . The LDL apo B production rate was calculated from the fractional catabolic rate for LDL, pool volume and LDL apo B concentration and expressed as milligrams per kilogram of body weight per day. 
Statistical analysis
The data analyses were performed with the Statistical Package for Social Sciences (SPSS version 14.0) software. A value of P < 0.05 was considered significant. The correlation coefficients were calculated by either Pearson's or Spearman's rank correlation method, as appropriate. Independent samples' t-test, ANOVA with Bonferroni correction, non-parametric Mann-Whitney U-test or Kruskall-Wallis test were used to test the significance of the differences between means, as appropriate. Stepwise linear regression analysis was used to test the explanatory strength of different factors. Analysis of covariance was performed to assess the independent associations between the studied variables.
Results
Subject characteristics
A total of 21 (37%) female and 36 (63%) male patients with chronic kidney disease (CKD) completed the study. Their clinical characteristics are shown in Table 1 . The mean age was similar in both sexes as were the mean creatinine and urea concentrations, but the mean eGFR was significantly lower for females (26 mL/min/1.73 m 2 ) than for males (36 mL/min/1.73 m 2 ) (P = 0.012). The miscellaneous renal diagnosis group consisted of patients with tubulointerstitial nephropathy, atherosclerosis or nephrosclerosis, renal dysgenesis, reflux nephropathy and medullary cystic disease or renal failure of unknown origin. Diabetes had been diagnosed in 14 patients (25%), with the mean duration of diabetes being 25.6 years. All of the patients were on conservative therapy (not on dialysis or transplantation). The use of any lipid-lowering drugs had been discontinued for at least 6 weeks prior to the studies. The patients were consuming their habitual diet, which was not changed during the studies. Five patients were current smokers (9%), whereas 31 (54%) patients had never smoked, and 21 (37%) were previous smokers. The mean age of the control subjects was 50 years with a range of 24-64 years (P = 0.167 for difference between renal patients and controls). Six of the 10 control subjects were males.
Plasma lipids and lipoproteins and clearance, production rates and concentrations of LDL apo B
The concentrations of plasma lipids and lipoproteins and the clearance and production rates and concentrations of LDL apo B in the CKD patients and controls are shown in Table 2 . Overall, the mean LDL FCR did not differ significantly between the two groups. However, LDL FCR varied widely in the renal study group, and altogether 25 out of the 57 CKD patients had LDL FCR values less than the minimum of the control subjects. In the renal patients, LDL FCR was negatively correlated with the total cholesterol (r = −0.422, P = 0.001) and LDL cholesterol (r = −0.578, P < 0.0001), but not with age, BMI or sex. Furthermore, among the renal patients, LDL FCR was positively correlated with eGFR (r = 0.340, P = 0.010) (Figure 1 ) and negatively with serum creatinine concentration (r = −0.313, P = 0.018). To further assess the association between LDL FCR and renal function, the CKD patients were divided into three groups based on eGFR values (Table 3) The mean values of LDL apo B production rates and concentrations (Table 2) did not differ significantly between the CKD and control groups. Among the CKD patients, the LDL apo B production rate correlated significantly with LDL apo B concentration (r = 0.510, P < 0.0001) and with eGFR (r = 0.264, P = 0.047) but not with LDL cholesterol concentration. The LDL apo B concentration correlated significantly with total cholesterol (r = 0.541, P < 0.0001) and LDL cholesterol (r = 0.513, P < 0.0001) but not with sex, age, BMI or degree of renal dysfunction in the CKD group.
A multiple linear regression model was constructed to explain the variation of LDL FCR among the CKD patients, and LDL cholesterol concentration and eGFR together explained 47.1% of the total variation of LDL FCR (adjusted R 2 , P < 0.0001). In contrast, age, gender and BMI had no statistically significant effect. Estimated GFR alone explained 12.5% of the total variation of LDL FCR (P = 0.004). Furthermore, in analysis of covariance with sex, presence of diabetes, age, BMI, LDL cholesterol concentration and eGFR included, LDL cholesterol concentration and eGFR remained independently associated with LDL FCR (P < 0.001 and P = 0.004, respectively) in the CKD patients. The presence of diabetes was not significantly associated with LDL FCR, and after the exclusion of diabetic patients from the covariance analysis, equal results were obtained (P < 0.001 and P = 0.019 for the associations between LDL FCR and LDL cholesterol concentration and between LDL FCR and eGFR, respectively).
In linear regression analysis, LDL apo B concentration, age and eGFR together explained 25.9% of the variation in LDL apo B production rate (P < 0.0001) in the CKD patients, whereas in analysis of covariance eGFR was not significantly associated with LDL apo B production rate. In linear regression analysis, LDL apo B concentration was best predicted by LDL cholesterol concentration (adjusted R 2 32.1%, P < 0.001) in the CKD patients, whereas sex, Table 3 . LDL apo B fractional catabolic rates, production rates and concentrations in 57 CKD patients divided into three groups based on the estimated glomerular filtration rate and in 10 control subjects age, BMI, presence of diabetes or eGFR were not significant predictors in this model.
Discussion
The major finding of the present study was that LDL clearance is related to the renal function. LDL clearance was shown to be significantly decreased in severe renal impairment, whereas in patients with mild to moderate kidney failure, LDL metabolism remained comparable to that of control subjects. LDL FCR has been assessed in several previous studies. We have previously demonstrated that the mean LDL FCR was 0.36 pools/day in normal subjects, 0.34 pools/day in obese subjects and 0.41 pools/day in patients with coronary heart disease [18] . In patients with FH, the mean LDL FCR was low, 0.19 pools/day [19] . In the present study, several renal patients displayed LDL FCR values even lower than that observed among the FH patients, and 25 patients (44%) showed LDL FCR lower than the minimum of the control subjects. We have previously shown impaired clearance of LDL in patients on continuous ambulatory peritoneal dialysis, whereas patients on haemodialysis did not differ significantly from control subjects [10] . Interestingly, a recent study detected 50% lower LDL FCR and 65% lower IDL apo B FCR values in uraemic patients receiving haemodialysis treatment compared with controls even though they had normal plasma cholesterol levels [20] . In the present study, we observed a significant correlation between LDL FCR and the remaining renal function. Patients with estimated GFRs <15 mL/min/1.73 m 2 presented with significantly lower LDL FCRs than patients with better yet abnormal GFRs. The present study confirms the results of our previous study on 12 patients with severe renal insufficiency [mean GFR 16.4 (SD 11.4) mL/min/1.73 m 2 ], which revealed lowered LDL catabolism in CKD [7] , but adds on new information suggesting that this defect becomes more apparent only when GFR is reduced to the level of severe kidney failure.
LDL metabolism of uraemia has also been studied in experimental chronic renal failure in animal models. In a partially nephrectomized guinea pig model, the FCR of native (control) LDL was slower in uraemic animals than in controls [9] . Furthermore, the FCR of uraemic LDL was reduced compared to that of control LDL in both uraemic and control animals [9] . Uraemic human LDL has also been shown to be cleared more slowly in rabbits than control human LDL [21] . These findings point to defects both in the LDL receptor and the LDL particle itself.
Contrary to LDL clearance, LDL apo B production rates were not independently associated with renal function in CKD patients in our study although there was a trend of decreased LDL apo B production rate in patients with more severe renal failure. Furthermore, LDL apo B production rates were comparable in the CKD group and in the controls. A similar finding was seen in our former study with 12 CKD patients [7] . In haemodialysis or peritoneal dialysis patients, LDL apo B production has been shown to be decreased compared to controls [10, 20] . In dialysis patients, LDL apo B concentration has been shown to be similar to that of control subjects [10, 20] as well as in patients with severe renal failure not on dialysis treatment in our previous study [7] . A possible mechanism for the constant LDL apo B concentration in our study may be the decreased catabolism of IDL apo B to LDL apo B [20] , whereas little is known about the direct hepatic production of apo B in CKD. It has also been shown that synthesis rather than clearance is an important factor determining plasma LDL apo B and LDL cholesterol concentrations in non-FH patients [22] .
In chronic renal failure altered lipoprotein metabolism is more clearly seen in the apolipoprotein profile and the lipoprotein composition than in lipoprotein concentrations. There are numerous factors that contribute to renal dyslipoproteinaemia including decreased activity of lipolytic enzymes and alterations in the lipoprotein substrate possibly affecting receptor recognition (apolipoprotein changes, modifications of lipoproteins) and decreased uptake of lipoproteins, as reviewed recently [23] . An interesting recent finding is that, in 5/6 nephrectomized rats, the hepatic LDL receptor-related protein (LRP) was down-regulated at the level of gene transcription [24] , which could reflect depressed clearance of chylomicron remnants and IDL. Carbamylation of LDL, which is known to occur in uraemia [25] , has been shown to affect LDL clearance [26] .
The clinical significance of decreased LDL clearance with normal or even low LDL cholesterol concentrations in CKD is unclear. In patients not on dialysis, LDL cholesterol levels did not have a significant relation with CVD mortality after adjustments for malnutrition, inflammation and cachexia [27] , suggesting that in CKD the LDL cholesterol concentration per se may not be as major a risk factor for CVD as in subjects without CKD. However, a longer residence time in the uraemic milieu may predispose LDL to atherogenic changes such as oxidation and non-receptormediated uptake by macrophages. In that case, treatment with lipid-lowering drugs, especially statins that inhibit cholesterol synthesis and increase IDL and LDL uptake by the liver, would be of benefit to reduce the levels of more atherogenic LDL. Interestingly, according to data from the United States Renal Data System, statin use has been associated with a reduction in cardiovascular deaths in patients on dialysis [28] , and in a meta-analysis with subjects with moderate renal failure, statin treatment reduced cardiovascular risk by 23-25% [29] . There are ongoing studies addressing the beneficial effects of statin treatment in conservatively treated and dialyzed CKD patients [30, 31] .
In conclusion, this study shows that LDL metabolism is altered in relation to the severity of renal dysfunction. LDL catabolism seems to be significantly reduced only in patients with advanced renal failure.
